REFERENCES
- Cogan DG. Ocular correlates of inborn metabolic defects. Can Med Assoc J. 1966;19;95(21):1055–1065.
- Crawford JS. Repair of ptosis using frontalis musckle and fascia lata. Trans Am Acad Ophthalmol Otolaryngol 1956;60(5):672–678.
- De Wilde F, D’Haens M, Smet H, Martin JJ, Tassignon MJ. Surgical treatment of myogenic blepharoptosis. Bull Soc Belge Ophtalmol 1995;255:139–146
- Groen WB, Leen WG, Vos AM, Cruysberg JR, van Doorn PA, van Engelen BG. Ptosis as a feature of late-onset glycogenosis type II. Neurology 2006;67:2261–2262.
- Kishani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL et al. Recombinant human acid α-glucosidase; Major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99–109.
- Prall FR, Drack A, Taylor M. Ophthalmic manifestations of Danon disease. Ophthalmology. 2006;113(6):1010–1013.
- Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356(9227):397–398.
- Van der Ploeg AT, Reuser AJJ. Lysosomal Storage Disease 2 Pompe’s disease. Lancet 2008;372:1342–153
- Yanovitch TL, Banugaria SG, Proia AD, Kishnani PS. Clinical and histologic ocular findings in pompe disease. J Pediatr Ophtalmol Strabismus 2010;47(1):34–40.